Qube Research & Technologies LTD Adaptimmune Therapeutics PLC Transaction History

Qube Research & Technologies LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.43 - $0.79 $8,373 - $15,384	-19,474 Reduced 90.32%	2,087 $1,000
Q3 2023 Nov 13, 2023	SELL	$0.73 - $1.04 $57,369 - $81,732	-78,589 Reduced 78.47%	21,561 $16,000
Q2 2023 Aug 14, 2023	BUY	$0.9 - $1.51 $47,093 - $79,012	52,326 Added 109.41%	100,150 $92,000
Q1 2023 May 15, 2023	BUY	$1.06 - $2.16 $22,072 - $44,977	20,823 Added 77.12%	47,824 $52,000
Q4 2022 Feb 14, 2023	BUY	$1.05 - $2.53 $28,351 - $68,312	27,001 New	27,001 $39,000
Q2 2022 Aug 15, 2022	BUY	$1.33 - $2.28 $58,474 - $100,242	43,966 New	43,966 $75,000
Q2 2020 Aug 14, 2020	SELL	$2.58 - $12.1 $31,390 - $147,220	-12,167 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.2 - $4.52 $14,600 - $54,994	12,167 New	12,167 $33,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $114M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.